<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03048422</url>
  </required_header>
  <id_info>
    <org_study_id>IMPAACT 2010</org_study_id>
    <secondary_id>30129</secondary_id>
    <nct_id>NCT03048422</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants</brief_title>
  <acronym>VESTED</acronym>
  <official_title>Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to compare the virologic efficacy and safety of three&#xD;
      antiretroviral (ARV) regimens, dolutegravir plus emtricitabine/tenofovir alafenamide,&#xD;
      dolutegravir plus emtricitabine/tenofovir disoproxil fumarate, and&#xD;
      efavirenz/emtricitabine/tenofovir disoproxil fumarate in pregnant women living with HIV-1 and&#xD;
      to compare the safety of these regimens for their infants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study compared the virologic efficacy and safety of three ARV regimens in pregnant women&#xD;
      living with HIV: dolutegravir (DTG) plus emtricitabine/tenofovir alafenamide (FTC/TAF), DTG&#xD;
      plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), and&#xD;
      efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF). The study also compared&#xD;
      the safety of these regimens for their infants.&#xD;
&#xD;
      At study entry, mothers were randomly assigned to either receive DTG plus FTC/TAF (Arm 1),&#xD;
      DTG plus FTC/TDF (Arm 2), or EFV/FTC/TDF (Arm 3) during pregnancy, through delivery, and for&#xD;
      50 weeks postpartum.&#xD;
&#xD;
      Mothers completed study visits at study entry and every four weeks during pregnancy. Study&#xD;
      visits for mothers and their infants occurred at delivery and at 6, 14, 26, 38, and 50 weeks&#xD;
      postpartum. Visits for mothers and infants included physical examinations and blood&#xD;
      collection. Select study visits also included breast milk collection from mothers who&#xD;
      breastfed, hair and urine collection, ultrasound scans, pregnancy testing, contraception&#xD;
      counseling, and, for a subset of participants, dual energy x-ray absorptiometry (DXA) scans&#xD;
      for mothers and their infants.&#xD;
&#xD;
      For pregnancy outcome measures, mothers and infants were evaluated together as mother-infant&#xD;
      pairs, with any outcome between the two counting as an event (for example, if an infant was&#xD;
      born small for gestational age, this would be a pregnancy outcome event for the mother-infant&#xD;
      pair). For all other outcome measures, women and infants were evaluated separately.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 19, 2018</start_date>
  <completion_date type="Actual">October 3, 2020</completion_date>
  <primary_completion_date type="Actual">October 3, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Mothers With HIV-1 RNA Viral Load Less Than 200 Copies/mL at Delivery</measure>
    <time_frame>Delivery</time_frame>
    <description>Percentage of mothers with plasma HIV-1 RNA viral load less than 200 copies/mL at delivery determined using real-time test results obtained at site laboratories. This outcome was evaluated in the non-inferiority (primary outcome) and superiority (secondary outcome) analyses. The intention-to-treat analysis included all randomized women who had viral load data available. The per-protocol analysis excluded women who modified randomized treatment (stopped, paused, switched, added any treatment) before viral load evaluation at delivery, with the exception of women who modified randomized treatment for use of a concomitant medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Mother-infant Pairs With an Adverse Pregnancy Outcome</measure>
    <time_frame>Delivery</time_frame>
    <description>Percentage of mother-infant pairs with an adverse pregnancy outcome. Adverse pregnancy outcome includes spontaneous abortion (&lt;20 weeks gestation), stillbirth (≥20 weeks gestation), preterm delivery (&lt;37 completed weeks), or small for gestational age (&lt;10th percentile by INTERGROWTH 21st Standards)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Probability of Women Experiencing Grade 3 or Higher Adverse Event</measure>
    <time_frame>From randomization up to 74 weeks</time_frame>
    <description>The Kaplan-Meier estimate of the cumulative probability of women experiencing grade 3 or higher adverse events, including events resulting in death due to any cause.&#xD;
Time to first maternal grade 3 or higher adverse event was defined as the first grade 3 or higher adverse event that occurred after randomization and before 74 weeks of follow-up. The timeframe of 74 weeks was determined by adding up 56 weeks of postpartum follow-up to the mean duration of antepartum follow-up, which was 18 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Probability of Infants Experiencing Grade 3 or Higher Adverse Event</measure>
    <time_frame>From birth through Week 50 postpartum</time_frame>
    <description>The Kaplan-Meier estimate of the cumulative probability of infants experiencing grade 3 or higher adverse events, including events resulting in death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Mothers With HIV-1 RNA Less Than 50 Copies/mL at Delivery Measured at Central Laboratory</measure>
    <time_frame>Delivery</time_frame>
    <description>Percentage of mothers with HIV-1 RNA less than 50 copies/mL at delivery using batched test results obtained from central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Mothers With HIV-1 RNA Less Than 200 Copies/mL at 50 Weeks Postpartum</measure>
    <time_frame>50 weeks postpartum</time_frame>
    <description>Percentage of mothers with HIV-1 RNA less than 200 copies/mL at 50 weeks postpartum using real-time test results obtained from site laboratories</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First HIV-1 RNA Less Than 200 Copies/mL Through Delivery</measure>
    <time_frame>Randomization to delivery</time_frame>
    <description>Time to first viral HIV-1 RNA less than 200 copies/mL through delivery, determined using real-time results obtained from site laboratories</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Mothers With Virologic Success of HIV-1 RNA Less Than 200 Copies/mL at Delivery Based on FDA Snapshot Algorithm</measure>
    <time_frame>Delivery</time_frame>
    <description>Percentage of mothers with virologic success of HIV-1 RNA less than 200 copies/mL at delivery based on FDA snapshot algorithm using real-time test results obtained from site laboratories</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Mothers With Virologic Success of HIV-1 RNA Less Than 200 Copies/mL at 50 Weeks Postpartum Based on FDA Snapshot Algorithm</measure>
    <time_frame>50 weeks postpartum</time_frame>
    <description>Percentage of mothers with virologic success of HIV-1 RNA less than 200 copies/mL at 50 weeks postpartum based on FDA snapshot algorithm using real-time test results obtained from site laboratories</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Mother-Infant Pairs With an Adverse Pregnancy Outcome</measure>
    <time_frame>Delivery</time_frame>
    <description>Percentage of mother-infant pairs with an adverse pregnancy outcome. Adverse pregnancy outcome includes spontaneous abortion (&lt;20 weeks gestation), stillbirth (≥20 weeks gestation), preterm delivery (&lt;37 completed weeks), or small for gestational age (&lt;10th percentile per INTERGROWTH 21st Standards)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Probability of Women Experiencing Grade 3 or Higher Adverse Event</measure>
    <time_frame>From randomization up to 74 weeks</time_frame>
    <description>The Kaplan-Meier estimate of the cumulative probability of women experiencing grade 3 or higher adverse events, including events resulting in death due to any cause.&#xD;
Time to first maternal grade 3 or higher adverse event was defined as the first grade 3 or higher adverse event that occurred after randomization and before 74 weeks of follow-up. The timeframe of 74 weeks was determined by adding up 56 weeks of postpartum follow-up to the mean duration of antepartum follow-up, which was 18 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Probability of Infants Experiencing Grade 3 or Higher Adverse Event</measure>
    <time_frame>Birth through Week 50 postpartum</time_frame>
    <description>The Kaplan-Meier estimate of the cumulative probability of infants experiencing grade 3 or higher adverse events, including events resulting in death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Mother-infant Pairs With an Adverse Pregnancy Outcome or Major Congenital Anomaly</measure>
    <time_frame>Delivery through 50 weeks postpartum</time_frame>
    <description>Percentage of mother-infant pairs with an adverse pregnancy outcome or major congenital anomaly. Adverse pregnancy outcomes include spontaneous abortions (&lt;20 weeks gestation), stillbirths (≥20 weeks gestation), preterm deliveries (&lt;37 weeks gestation), and infants small for gestational age (&lt;10th percentile per INTERGROWTH 21st Standards). Major congenital anomaly was defined consistent with the definition of malformation provided by Holmes and Westgate (i.e., a structural abnormality with surgical, medical, or cosmetic importance) and evaluated by an internal study team blinded to treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Mother-infant Pairs in the Classified Ranked Composite Safety Outcome</measure>
    <time_frame>Birth through 50 weeks postpartum</time_frame>
    <description>Infant and pregnancy outcomes were classified on a scale of 1 to 10, with mother-infant pairs categorized by the worst outcome they experienced (worst category being 1 and best being 10): 1) Infant death; 2) Spontaneous abortion (&lt;20 weeks gestation) or stillbirth (≥20 weeks gestation); 3) Infant HIV infection; 4) Extremely and very early preterm (&lt;32 completed weeks); 5) Major congenital anomaly; 6) Preterm delivery (&lt;37 completed weeks); 7) Small for gestational age (&lt;10th percentile); 8) Infant hospitalization; 9) Infant grade 3 or 4 adverse event; 10) None of the above. If a mother-infant pair experienced more than one safety outcome, only the worst was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Probability of Infant HIV-infection</measure>
    <time_frame>Birth through 50 weeks after birth</time_frame>
    <description>The Kaplan-Meier estimate of the cumulative probability of infants acquiring HIV-1 infection from birth through 50 weeks after birth based on nucleic acid test results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Probability of Infant Deaths</measure>
    <time_frame>Birth through 50 weeks after birth</time_frame>
    <description>The Kaplan-Meier estimate of the cumulative probability of infant deaths from birth through 50 weeks after birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Change in Creatinine Clearance</measure>
    <time_frame>Baseline to 50 weeks postpartum</time_frame>
    <description>Maternal change in creatinine clearance per week based on generalized estimating equations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant Creatinine Clearance</measure>
    <time_frame>Delivery and 26 weeks postpartum</time_frame>
    <description>Infant creatinine clearance based on Schwartz formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Mothers With HIV-1 ARV Drug Resistance Mutations at the Time of Maternal Virologic Failure</measure>
    <time_frame>From 24 weeks after randomization through Week 50 postpartum</time_frame>
    <description>Percentage of mothers with HIV-1 antiretroviral (ARV) drug resistance mutations at the time of maternal virologic failure. Virologic failure was defined as two consecutive plasma HIV-1 RNA viral loads &lt;200 copies/mL on or after 24 weeks on study. Drug resistance mutations were assessed using the Stanford algorithm, and all ARV regimens were assessed for mutations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Infants With HIV-1 Antiretroviral Drug Resistance Mutations at the Time of Infant HIV Diagnosis</measure>
    <time_frame>From birth through 50 weeks postpartum</time_frame>
    <description>Percentage of infants with HIV-1 antiretroviral drug resistance mutations at the time of infant HIV diagnosis, based on laboratory blood test results.&#xD;
Data for this outcome are not yet available because shipping delays due to COVID-19.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Preterm Deliveries</measure>
    <time_frame>Delivery</time_frame>
    <description>Percentage of preterm deliveries (&lt;37 weeks gestation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Infants Born Small for Gestational Age</measure>
    <time_frame>Birth</time_frame>
    <description>Percentage of infants born small for gestational age (&lt;10th percentile adjusted for sex assigned at birth) based on Intergrowth 21st Standards</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Maternal Weight Antepartum</measure>
    <time_frame>Baseline through before delivery (up to one day prior)</time_frame>
    <description>Change in maternal antepartum weight per week based on generalized estimating equations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Maternal Weight Postpartum</measure>
    <time_frame>Delivery to 50 weeks postpartum</time_frame>
    <description>Change in maternal postpartum weight per week based on generalized estimating equations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Maternal Weight Overall</measure>
    <time_frame>Baseline to 50 weeks postpartum</time_frame>
    <description>Change in maternal weight per week based on generalized estimating equations</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">643</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Arm 1: Maternal DTG+FTC/TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mothers randomized to receive dolutegravir (DTG) plus emtricitabine/tenofovir alafenamide (FTC/TAF) during pregnancy, through delivery, and for 50 weeks postpartum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Maternal DTG+FTC/TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mothers randomized to receive DTG plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) during pregnancy, through delivery, and for 50 weeks postpartum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Maternal EFV/FTC/TDF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mothers randomized to receive efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) during pregnancy, through delivery, and for 50 weeks postpartum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1 Infants</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Infants born to women in Arm 1. Infants did not directly receive study intervention, but may have been exposed to the randomized treatment through placental or breastmilk transfer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 Infants</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Infants born to women in Arm 2. Infants did not directly receive study intervention, but may have been exposed to the randomized treatment through placental or breastmilk transfer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 Infants</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Infants born to women in Arm 3. Infants did not directly receive study intervention, but may have been exposed to the randomized treatment through placental or breastmilk transfer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir</intervention_name>
    <description>One 50 mg DTG tablet was administered orally once daily</description>
    <arm_group_label>Arm 1: Maternal DTG+FTC/TAF</arm_group_label>
    <arm_group_label>Arm 2: Maternal DTG+FTC/TDF</arm_group_label>
    <other_name>DTG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine/tenofovir alafenamide</intervention_name>
    <description>One fixed-dose combination tablet (FTC 200 mg/TAF 25 mg) was administered orally once daily</description>
    <arm_group_label>Arm 1: Maternal DTG+FTC/TAF</arm_group_label>
    <other_name>FTC/TAF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine/tenofovir disoproxil fumarate</intervention_name>
    <description>One fixed-dose combination tablet (FTC 200 mg/TDF 300 mg) was administered orally once daily</description>
    <arm_group_label>Arm 2: Maternal DTG+FTC/TDF</arm_group_label>
    <other_name>FTC/TDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz/emtricitabine/tenofovir disoproxil fumarate</intervention_name>
    <description>One fixed-dose combination tablet (EFV 600 mg/FTC 200 mg/TDF 300 mg) was administered orally once daily</description>
    <arm_group_label>Arm 3: Maternal EFV/FTC/TDF</arm_group_label>
    <other_name>EFV/FTC/TDF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mother is able to provide written informed consent for her and her infant's&#xD;
             participation in this study&#xD;
&#xD;
          -  Mother has confirmed HIV-1 infection based on documented testing of two samples&#xD;
             collected at different time points:&#xD;
&#xD;
               -  Sample #1 may be tested using any of the following:&#xD;
&#xD;
               -  Two rapid antibody tests from different manufacturers or based on different&#xD;
                  principles and epitopes&#xD;
&#xD;
               -  One enzyme immunoassay (EIA) OR Western blot OR immunofluorescence assay OR&#xD;
                  chemiluminescence assay&#xD;
&#xD;
               -  One HIV DNA polymerase chain reaction (PCR)&#xD;
&#xD;
               -  One quantitative HIV RNA PCR (above the limit of detection of the assay)&#xD;
&#xD;
               -  One qualitative HIV RNA PCR&#xD;
&#xD;
               -  One total HIV nucleic acid test&#xD;
&#xD;
               -  Sample #2 may be tested using any of the following:&#xD;
&#xD;
               -  One rapid antibody test. If this option is used in combination with two rapid&#xD;
                  tests for Sample #1, at least one of the three rapid tests must be FDA-approved&#xD;
                  and the third rapid test must be from a third manufacturer or based on a third&#xD;
                  principle or epitope.&#xD;
&#xD;
               -  One EIA OR Western blot OR immunofluorescence assay OR chemiluminescence assay&#xD;
&#xD;
               -  One HIV DNA PCR&#xD;
&#xD;
               -  One quantitative HIV RNA PCR (above the limit of detection of the assay)&#xD;
&#xD;
               -  One qualitative HIV RNA PCR&#xD;
&#xD;
               -  One total HIV nucleic acid test.&#xD;
&#xD;
               -  See the protocol for more information on this inclusion criterion.&#xD;
&#xD;
          -  At screening, mother is ART-naive, defined as having not received prior antiretroviral&#xD;
             therapy other than ARVs received during prior pregnancies or prior periods of&#xD;
             breastfeeding (i.e., receipt of any single, dual, or triple ARV regimen during prior&#xD;
             time-limited periods of pregnancy and breastfeeding is permitted). Receipt of up to 14&#xD;
             days of ARVs during the current pregnancy is permitted prior to study entry so that&#xD;
             initiation of ARVs during the current pregnancy is not delayed during the study&#xD;
             screening period. Note: Non-study ART may be initiated in the current pregnancy prior&#xD;
             to initiation of the study screening process. For eligible participants, enrollment&#xD;
             must occur within 14 days of non-study ART initiation. Note: Receipt of ARVs during a&#xD;
             prior pregnancy or prior period of breastfeeding must have concluded at least six&#xD;
             months prior to study entry. Receipt of TDF or FTC/TDF for pre-exposure prophylaxis at&#xD;
             any time in the past is not exclusionary (even if received within six months prior to&#xD;
             study entry).&#xD;
&#xD;
          -  At screening, mother has the following laboratory test results (based on testing of&#xD;
             samples collected within 14 days prior to study entry):&#xD;
&#xD;
               -  Grade 1 or lower (less than 2.5 times upper limit of normal [ULN]) alanine&#xD;
                  aminotransferase (ALT) and aspartate aminotransferase (AST)&#xD;
&#xD;
               -  Grade 2 or lower (less than or equal to 1.8 times ULN) creatinine&#xD;
&#xD;
               -  Grade 2 or lower (greater than or equal to 60 mL/min) estimated creatinine&#xD;
                  clearance (CrCl; Cockcroft-Gault formula). See the protocol for guidance on&#xD;
                  severity grading. Laboratory tests may be repeated during the study screening&#xD;
                  period, with the latest result used for eligibility determination.&#xD;
&#xD;
          -  At screening and at study entry, no evidence of multiple gestation or fetal anomalies,&#xD;
             as assessed by best available method&#xD;
&#xD;
          -  At study entry, gestational age of 14-28 weeks, defined as greater than 13 weeks plus&#xD;
             six days and less than 28 completed weeks gestation, estimated by best available&#xD;
             method. Note: For this inclusion criterion and the previous inclusion criterion, fetal&#xD;
             ultrasound is preferred but not required for purposes of eligibility determination. If&#xD;
             ultrasound cannot be performed during the study screening period prior to study entry,&#xD;
             it must be performed within 14 days after study entry. As further explained in the&#xD;
             protocol, enrolled participants will not be withdrawn from the study based on&#xD;
             ultrasound findings obtained after study entry.&#xD;
&#xD;
          -  At study entry, mother expects to remain in the geographic area of the study site&#xD;
             during pregnancy and for 50 weeks postpartum [Eligibility criteria added per Letter of&#xD;
             Amendment 1 to V2; July 2018]:&#xD;
&#xD;
          -  At study entry, mother reports that she does not wish to become pregnant again for at&#xD;
             least 50 weeks after her current pregnancy and that she is willing to use effective&#xD;
             contraception during this period. Effective contraception may include surgical&#xD;
             sterilization (i.e., hysterectomy, bilateral oophorectomy, tubal ligation, or&#xD;
             salpingectomy) or any of the following methods:&#xD;
&#xD;
               -  Contraceptive intrauterine device (IUD) or intrauterine system (IUS)&#xD;
&#xD;
               -  Subdermal contraceptive implant&#xD;
&#xD;
               -  Progestogen injections&#xD;
&#xD;
               -  Progestogen only oral contraceptive pills&#xD;
&#xD;
               -  Combined estrogen and progestogen oral contraceptive pills&#xD;
&#xD;
               -  Percutaneous contraceptive patches&#xD;
&#xD;
               -  Contraceptive vaginal rings&#xD;
&#xD;
               -  Note: IUDs, IUSs, implants, and injections are strongly recommended due to their&#xD;
                  lower failure rates with typical use. Male or female condom use is recommended&#xD;
                  with all contraceptive methods for dual protection against pregnancy and to avoid&#xD;
                  transmission of HIV and other sexually transmitted infections.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mother is currently incarcerated or involuntarily confined in a medical facility&#xD;
&#xD;
          -  Mother is currently receiving:&#xD;
&#xD;
               -  A psychoactive medication for treatment of a psychiatric illness&#xD;
&#xD;
               -  Treatment for active tuberculosis&#xD;
&#xD;
               -  Treatment for active hepatitis C infection&#xD;
&#xD;
          -  Mother is expected to require treatment with interferon and/or ribavirin for hepatitis&#xD;
             C infection during the study follow-up period&#xD;
&#xD;
          -  Mother has a history of any of the following, as determined by the site investigator&#xD;
             or designee based on maternal report and available medical records:&#xD;
&#xD;
               -  Hypersensitivity or clinically significant adverse reaction to any of the ARVs&#xD;
                  included in the three study drug regimens (ever)&#xD;
&#xD;
               -  Antiretroviral drug resistance mutations that would impact selection of ART&#xD;
                  regimen (ever)&#xD;
&#xD;
               -  Clinically significant heart disease and/or known prolonged corrected QT (QTc)&#xD;
                  interval (ever)&#xD;
&#xD;
               -  Suicidal ideation or attempt (ever)&#xD;
&#xD;
               -  HIV-2 infection (ever)&#xD;
&#xD;
               -  Zika virus infection, diagnosed or suspected, during the current pregnancy&#xD;
&#xD;
               -  Receipt of any antiretroviral medication within six months prior to study entry,&#xD;
                  with two exceptions: receipt of any duration of TDF or FTC/TDF for pre-exposure&#xD;
                  prophylaxis or receipt of up to 14 days of ARVs during the current pregnancy&#xD;
&#xD;
               -  Receipt of any prohibited medication within 14 days prior to study entry (see the&#xD;
                  protocol for more information)&#xD;
&#xD;
               -  Clinically significant acute illness requiring systemic treatment and/or&#xD;
                  hospitalization (i.e., major medical condition that is likely to lead to&#xD;
                  hospitalization and/or to an adverse pregnancy outcome) within 14 days prior to&#xD;
                  study entry&#xD;
&#xD;
               -  Unstable liver disease (defined by the presence of ascites, encephalopathy,&#xD;
                  coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent&#xD;
                  jaundice) or known biliary abnormalities (with the exception of Gilbert's&#xD;
                  syndrome or asymptomatic gallstones) within 14 days prior to study entry&#xD;
&#xD;
               -  Note: Testing to rule out HIV-2 infection is not required.&#xD;
&#xD;
          -  Mother or fetus has any other condition that, in the opinion of the site investigator&#xD;
             or designee, would make participation in the study unsafe, complicate interpretation&#xD;
             of study outcome data, or otherwise interfere with achieving the study objectives&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahin Lockman, MD, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Harvard T.H. Chan School of Public Health and Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lameck Chinula, MBBS, MMED, FCOG</last_name>
    <role>Study Chair</role>
    <affiliation>Kamuzu Central Hospital in Lilongwe, Malawi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ. of Florida Jacksonville NICHD CRS</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Perinatal HIV Clinical Trials Unit CRS</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gaborone CRS</name>
      <address>
        <city>Gaborone</city>
        <state>South-East District</state>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Molepolole CRS</name>
      <address>
        <city>Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOM Federal University Minas Gerais Brazil NICHD CRS</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30.130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Federal dos Servidores do Estado NICHD CRS</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>20221-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21941-612</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Geral De Nova Igaucu Brazil NICHD CRS</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>26030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Byramjee Jeejeebhoy Medical College (BJMC) CRS</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soweto IMPAACT CRS</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1862</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits RHI Shandukani Research Centre CRS</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umlazi CRS</name>
      <address>
        <city>Durban</city>
        <state>Kwa Zulu Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Famcru Crs</name>
      <address>
        <city>Tygerberg</city>
        <state>Western Cape Province</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kilimanjaro Christian Medical Centre (KCMC)</name>
      <address>
        <city>Moshi</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital ,Mahidol University NICHD CRS</name>
      <address>
        <city>Bangkok</city>
        <state>Bangkoknoi</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiangrai Prachanukroh Hospital NICHD CRS</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50100</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor-Uganda CRS</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seke North CRS</name>
      <address>
        <city>Chitungwiza</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mary's CRS</name>
      <address>
        <city>Chitungwiza</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harare Family Care CRS</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Botswana</country>
    <country>Brazil</country>
    <country>India</country>
    <country>South Africa</country>
    <country>Tanzania</country>
    <country>Thailand</country>
    <country>Uganda</country>
    <country>United States</country>
    <country>Zimbabwe</country>
  </location_countries>
  <removed_countries>
    <country>Haiti</country>
    <country>Malawi</country>
  </removed_countries>
  <link>
    <url>http://impaactnetwork.org/studies/impaact2010</url>
    <description>Study website</description>
  </link>
  <link>
    <url>http://rsc.niaid.nih.gov/clinical-research-sites/daids-adverse-event-grading-tables</url>
    <description>The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Corrected Version 2.1, dated July 2017, was used</description>
  </link>
  <link>
    <url>http://intergrowth21.tghn.org/standards-tools/</url>
    <description>Intergrowth 21st Standards, including reference for infants small for gestational age</description>
  </link>
  <link>
    <url>http://www.fda.gov/files/drugs/published/Human-Immunodeficiency-Virus-1-Infection--Developing-Antiretroviral-Drugs-for-Treatment.pdf</url>
    <description>FDA Snapshot algorithm</description>
  </link>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/21800414/</url>
    <description>Definition for major congenital anomalies</description>
  </link>
  <link>
    <url>http://www-users.med.cornell.edu/~spon/picu/calc/crclschw.htm</url>
    <description>Schwartz formula for calculating infant creatinine clearance</description>
  </link>
  <results_reference>
    <citation>Lockman S, Brummel SS, Ziemba L, Stranix-Chibanda L, McCarthy K, Coletti A, Jean-Philippe P, Johnston B, Krotje C, Fairlie L, Hoffman RM, Sax PE, Moyo S, Chakhtoura N, Stringer JS, Masheto G, Korutaro V, Cassim H, Mmbaga BT, João E, Hanley S, Purdue L, Holmes LB, Momper JD, Shapiro RL, Thoofer NK, Rooney JF, Frenkel LM, Amico KR, Chinula L, Currier J; IMPAACT 2010/VESTED Study Team and Investigators. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2021 Apr 3;397(10281):1276-1292. doi: 10.1016/S0140-6736(21)00314-7.</citation>
    <PMID>33812487</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2017</study_first_posted>
  <results_first_submitted>October 4, 2021</results_first_submitted>
  <results_first_submitted_qc>October 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 10, 2021</results_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Emtricitabine tenofovir alafenamide</mesh_term>
    <mesh_term>Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie results in the publication, after deidentification</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 3 months following publication and available throughout period of funding of the International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) Network by NIH</ipd_time_frame>
    <ipd_access_criteria>With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the IMPAACT Network.&#xD;
For what types of analyses? To achieve aims in the proposal approved by the IMPAACT Network.&#xD;
By what mechanism will data be made available? Researchers may submit a request for access to data using the IMPAACT &quot;Data Request&quot; form at: https://www.impaactnetwork.org/studies/submit-research-proposal. Researchers of approved proposals will need to sign an IMPAACT Data Use Agreement before receiving the data.</ipd_access_criteria>
    <ipd_url>https://www.impaactnetwork.org/studies/submit-research-proposal</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form: IMPAACT 2010 Protocol V2.0</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT03048422/Prot_ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: IMPAACT 2010 Protocol V2.0_Letter of Amendment 1</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT03048422/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: IMPAACT 2010 Protocol V2.0_Letter of Amendment 2</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 23, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT03048422/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: IMPAACT 2010 Protocol V2.0_Letter of Amendment 3</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 10, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT03048422/Prot_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 26, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT03048422/SAP_004.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Maternal DTG+FTC/TAF</title>
          <description>Mothers randomized to receive DTG+FTC/TAF</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Maternal DTG+FTC/TDF</title>
          <description>Mothers randomized to receive DTG+FTC/TDF</description>
        </group>
        <group group_id="P3">
          <title>Arm 3: Maternal EFV/FTC/TDF</title>
          <description>Mothers randomized to receive EFV/FTC/TDF</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="217"/>
                <participants group_id="P2" count="215"/>
                <participants group_id="P3" count="211"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="205"/>
                <participants group_id="P3" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliant with Study Requirements</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Able to Get to Clinic</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Enrolled women.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: Maternal DTG+FTC/TAF</title>
          <description>Mothers randomized to receive DTG+FTC/TAF</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Maternal DTG+FTC/TDF</title>
          <description>Mothers randomized to receive DTG+FTC/TDF</description>
        </group>
        <group group_id="B3">
          <title>Arm 3: Maternal EFV/FTC/TDF</title>
          <description>Mothers randomized to receive EFV/FTC/TDF</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="217"/>
            <count group_id="B2" value="215"/>
            <count group_id="B3" value="211"/>
            <count group_id="B4" value="643"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="217"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="211"/>
                    <count group_id="B4" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.5" spread="6.2"/>
                    <measurement group_id="B2" value="27.0" spread="5.8"/>
                    <measurement group_id="B3" value="27.7" spread="5.9"/>
                    <measurement group_id="B4" value="27.4" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="217"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="211"/>
                    <count group_id="B4" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                    <measurement group_id="B2" value="215"/>
                    <measurement group_id="B3" value="211"/>
                    <measurement group_id="B4" value="643"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="217"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="211"/>
                    <count group_id="B4" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="190"/>
                    <measurement group_id="B4" value="576"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="217"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="211"/>
                    <count group_id="B4" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="194"/>
                    <measurement group_id="B4" value="585"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="217"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="211"/>
                    <count group_id="B4" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Botswana</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="217"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="211"/>
                    <count group_id="B4" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tanzania</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="217"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="211"/>
                    <count group_id="B4" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="217"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="211"/>
                    <count group_id="B4" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="217"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="211"/>
                    <count group_id="B4" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uganda</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="217"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="211"/>
                    <count group_id="B4" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zimbabwe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="217"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="211"/>
                    <count group_id="B4" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="217"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="211"/>
                    <count group_id="B4" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="217"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="211"/>
                    <count group_id="B4" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="217"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="211"/>
                    <count group_id="B4" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.6" spread="4.2"/>
                    <measurement group_id="B2" value="21.4" spread="4.2"/>
                    <measurement group_id="B3" value="21.8" spread="4.2"/>
                    <measurement group_id="B4" value="21.6" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational Age Stratification Group</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>14-18 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="217"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="211"/>
                    <count group_id="B4" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19-23 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="217"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="211"/>
                    <count group_id="B4" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-28 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="217"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="211"/>
                    <count group_id="B4" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma HIV-1 RNA Viral Load</title>
          <population>Plasma HIV RNA viral load among participants who had baseline viral load data available.</population>
          <units>copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="216"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="209"/>
                    <count group_id="B4" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14,558.2" spread="45,813.9"/>
                    <measurement group_id="B2" value="18,420.3" spread="97,896.4"/>
                    <measurement group_id="B3" value="13,381.2" spread="42,042.5"/>
                    <measurement group_id="B4" value="15,471.2" spread="67,050.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma HIV-1 RNA Viral Load &lt;200 copies/mL</title>
          <population>Participants with plasma HIV-1 RNA viral load data available at baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="216"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="209"/>
                    <count group_id="B4" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="217"/>
                    <count group_id="B2" value="215"/>
                    <count group_id="B3" value="211"/>
                    <count group_id="B4" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.7" spread="15.1"/>
                    <measurement group_id="B2" value="66.3" spread="16.8"/>
                    <measurement group_id="B3" value="64.5" spread="13.3"/>
                    <measurement group_id="B4" value="66.2" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Mothers With HIV-1 RNA Viral Load Less Than 200 Copies/mL at Delivery</title>
        <description>Percentage of mothers with plasma HIV-1 RNA viral load less than 200 copies/mL at delivery determined using real-time test results obtained at site laboratories. This outcome was evaluated in the non-inferiority (primary outcome) and superiority (secondary outcome) analyses. The intention-to-treat analysis included all randomized women who had viral load data available. The per-protocol analysis excluded women who modified randomized treatment (stopped, paused, switched, added any treatment) before viral load evaluation at delivery, with the exception of women who modified randomized treatment for use of a concomitant medication.</description>
        <time_frame>Delivery</time_frame>
        <population>Women who had plasma HIV-1 RNA viral load data available at delivery</population>
        <group_list>
          <group group_id="O1">
            <title>Arms 1 and 2: Maternal DTG+FTC/TAF and DTG+FTC/TDF</title>
            <description>Combined group of mothers randomized to receive dolutegravir DTG+FTC/TAF or DTG+FTC/TDF</description>
          </group>
          <group group_id="O2">
            <title>Arm 3: Maternal EFV/FTC/TDF</title>
            <description>Mothers randomized to receive EFV/FTC/TDF</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Mothers With HIV-1 RNA Viral Load Less Than 200 Copies/mL at Delivery</title>
          <description>Percentage of mothers with plasma HIV-1 RNA viral load less than 200 copies/mL at delivery determined using real-time test results obtained at site laboratories. This outcome was evaluated in the non-inferiority (primary outcome) and superiority (secondary outcome) analyses. The intention-to-treat analysis included all randomized women who had viral load data available. The per-protocol analysis excluded women who modified randomized treatment (stopped, paused, switched, added any treatment) before viral load evaluation at delivery, with the exception of women who modified randomized treatment for use of a concomitant medication.</description>
          <population>Women who had plasma HIV-1 RNA viral load data available at delivery</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="405"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intention-to-Treat Analysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5"/>
                    <measurement group_id="O2" value="91.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per-Protocol Analysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5"/>
                    <measurement group_id="O2" value="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in proportions for intention-to-treat analysis.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin was a 10% difference between groups.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.0</ci_lower_limit>
            <ci_upper_limit>10.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in proportions for per-protocol analysis.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin was a 10% difference between groups.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>6.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.6</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in proportions for superiority and intention-to-treat analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.0</ci_lower_limit>
            <ci_upper_limit>10.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Mother-infant Pairs With an Adverse Pregnancy Outcome</title>
        <description>Percentage of mother-infant pairs with an adverse pregnancy outcome. Adverse pregnancy outcome includes spontaneous abortion (&lt;20 weeks gestation), stillbirth (≥20 weeks gestation), preterm delivery (&lt;37 completed weeks), or small for gestational age (&lt;10th percentile by INTERGROWTH 21st Standards)</description>
        <time_frame>Delivery</time_frame>
        <population>Mother-infant pairs with pregnancy outcome evaluated on study.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Maternal DTG+FTC/TAF</title>
            <description>Mothers randomized to receive DTG+FTC/TAF</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Maternal DTG+FTC/TDF</title>
            <description>Mothers randomized to receive DTG+FTC/TDF</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Maternal EFV/FTC/TDF</title>
            <description>Mothers randomized to receive EFV/FTC/TDF</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Mother-infant Pairs With an Adverse Pregnancy Outcome</title>
          <description>Percentage of mother-infant pairs with an adverse pregnancy outcome. Adverse pregnancy outcome includes spontaneous abortion (&lt;20 weeks gestation), stillbirth (≥20 weeks gestation), preterm delivery (&lt;37 completed weeks), or small for gestational age (&lt;10th percentile by INTERGROWTH 21st Standards)</description>
          <population>Mother-infant pairs with pregnancy outcome evaluated on study.</population>
          <units>percentage of mother-infant pairs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="213"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1"/>
                    <measurement group_id="O2" value="32.9"/>
                    <measurement group_id="O3" value="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between groups (DTG+FTC/TAF - DTG+FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.043</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-8.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.3</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between groups (DTG+FTC/TDF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.8</ci_lower_limit>
            <ci_upper_limit>9.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between groups (DTG+FTC/TAF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-8.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.1</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Probability of Women Experiencing Grade 3 or Higher Adverse Event</title>
        <description>The Kaplan-Meier estimate of the cumulative probability of women experiencing grade 3 or higher adverse events, including events resulting in death due to any cause.&#xD;
Time to first maternal grade 3 or higher adverse event was defined as the first grade 3 or higher adverse event that occurred after randomization and before 74 weeks of follow-up. The timeframe of 74 weeks was determined by adding up 56 weeks of postpartum follow-up to the mean duration of antepartum follow-up, which was 18 weeks.</description>
        <time_frame>From randomization up to 74 weeks</time_frame>
        <population>Enrolled women.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Maternal DTG+FTC/TAF</title>
            <description>Mothers randomized to receive DTG+FTC/TAF</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Maternal DTG+FTC/TDF</title>
            <description>Mothers randomized to receive DTG+FTC/TDF</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Maternal EFV/FTC/TDF</title>
            <description>Mothers randomized to receive EFV/FTC/TDF</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Probability of Women Experiencing Grade 3 or Higher Adverse Event</title>
          <description>The Kaplan-Meier estimate of the cumulative probability of women experiencing grade 3 or higher adverse events, including events resulting in death due to any cause.&#xD;
Time to first maternal grade 3 or higher adverse event was defined as the first grade 3 or higher adverse event that occurred after randomization and before 74 weeks of follow-up. The timeframe of 74 weeks was determined by adding up 56 weeks of postpartum follow-up to the mean duration of antepartum follow-up, which was 18 weeks.</description>
          <population>Enrolled women.</population>
          <units>Cumulative probability per 100 persons</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1"/>
                    <measurement group_id="O2" value="30.8"/>
                    <measurement group_id="O3" value="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The Kaplan-Meier method was used to estimate survival probabilities. Survival probabilities were compared based on a Z-test using Greenwoods estimate of the standard error. The null hypothesis was no difference between arms (DTG+FTC/TAF - DTG+FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.098</p_value>
            <method>Z-test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-5.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.2</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The Kaplan-Meier method was used to estimate survival probabilities. Survival probabilities were compared based on a Z-test using Greenwoods estimate of the standard error. The null hypothesis was no difference between arms (DTG+FTC/TDF-EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Z-test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.9</ci_lower_limit>
            <ci_upper_limit>11.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The Kaplan-Meier method was used to estimate survival probabilities. Survival probabilities were compared based on a Z-test using Greenwoods estimate of the standard error. The null hypothesis was no difference between arms (DTG+FTC/TAF-EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Z-test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.3</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Probability of Infants Experiencing Grade 3 or Higher Adverse Event</title>
        <description>The Kaplan-Meier estimate of the cumulative probability of infants experiencing grade 3 or higher adverse events, including events resulting in death due to any cause.</description>
        <time_frame>From birth through Week 50 postpartum</time_frame>
        <population>Live born infants</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 Infants</title>
            <description>Infants born to women who were randomized to receive DTG+FTC/TAF during pregnancy and postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 Infants</title>
            <description>Infants born to women who were randomized to receive DTG+FTC/TDF during pregnancy and postpartum</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 Infants</title>
            <description>Infants born to women who were randomized to receive EFV/FTC/TDF during pregnancy and postpartum</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Probability of Infants Experiencing Grade 3 or Higher Adverse Event</title>
          <description>The Kaplan-Meier estimate of the cumulative probability of infants experiencing grade 3 or higher adverse events, including events resulting in death due to any cause.</description>
          <population>Live born infants</population>
          <units>Cumulative probability per 100 persons</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The Kaplan-Meier method was used to estimate survival probabilities. Comparisons of survival probabilities was based on a Z-test using Greenwoods estimate of the standard error. The null hypothesis was no difference between arms, with estimated difference of DTG+FTC/TAF - DTG+FTC/TDF.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Z-test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.8</ci_lower_limit>
            <ci_upper_limit>6.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The Kaplan-Meier method was used to estimate survival probabilities. Comparisons of survival probabilities was based on a Z-test using Greenwoods estimate of the standard error. The null hypothesis was no difference between arms, with estimate of risk difference DTG+FTC/TDF-EFV/FTC/TDF.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Z-test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.1</ci_lower_limit>
            <ci_upper_limit>7.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The Kaplan-Meier method was used to estimate survival probabilities. Comparisons of survival probabilities was based on a Z-test using Greenwoods estimate of the standard error. The null hypothesis was no difference between arms, with estimate of risk difference DTG+FTC/TAF-EFV/FTC/TDF.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Z-test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-5.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.3</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Mothers With HIV-1 RNA Less Than 50 Copies/mL at Delivery Measured at Central Laboratory</title>
        <description>Percentage of mothers with HIV-1 RNA less than 50 copies/mL at delivery using batched test results obtained from central laboratory</description>
        <time_frame>Delivery</time_frame>
        <population>Women with viral load data available from central laboratory</population>
        <group_list>
          <group group_id="O1">
            <title>Arms 1 and 2: Maternal DTG+FTC/TAF and DTG+FTC/TDF</title>
            <description>Combined group of mothers randomized to receive dolutegravir DTG+FTC/TAF or DTG+FTC/TDF</description>
          </group>
          <group group_id="O2">
            <title>Arm 3: Maternal EFV/FTC/TDF</title>
            <description>Mothers randomized to receive EFV/FTC/TDF</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Mothers With HIV-1 RNA Less Than 50 Copies/mL at Delivery Measured at Central Laboratory</title>
          <description>Percentage of mothers with HIV-1 RNA less than 50 copies/mL at delivery using batched test results obtained from central laboratory</description>
          <population>Women with viral load data available from central laboratory</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4"/>
                    <measurement group_id="O2" value="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in proportions between arms for intention-to-treat analysis with null hypothesis of no difference (DTG groups - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>15.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.3</ci_lower_limit>
            <ci_upper_limit>22.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Mothers With HIV-1 RNA Less Than 200 Copies/mL at 50 Weeks Postpartum</title>
        <description>Percentage of mothers with HIV-1 RNA less than 200 copies/mL at 50 weeks postpartum using real-time test results obtained from site laboratories</description>
        <time_frame>50 weeks postpartum</time_frame>
        <population>Women with viral load data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Arms 1 and 2: Maternal DTG+FTC/TAF and DTG+FTC/TDF</title>
            <description>Combined group of mothers randomized to receive dolutegravir DTG+FTC/TAF or DTG+FTC/TDF</description>
          </group>
          <group group_id="O2">
            <title>Arm 3: Maternal EFV/FTC/TDF</title>
            <description>Mothers randomized to receive EFV/FTC/TDF</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Mothers With HIV-1 RNA Less Than 200 Copies/mL at 50 Weeks Postpartum</title>
          <description>Percentage of mothers with HIV-1 RNA less than 200 copies/mL at 50 weeks postpartum using real-time test results obtained from site laboratories</description>
          <population>Women with viral load data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="380"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3"/>
                    <measurement group_id="O2" value="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in proportions for intention-to-treat analysis with null hypothesis of no difference between arms (DTG arms - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First HIV-1 RNA Less Than 200 Copies/mL Through Delivery</title>
        <description>Time to first viral HIV-1 RNA less than 200 copies/mL through delivery, determined using real-time results obtained from site laboratories</description>
        <time_frame>Randomization to delivery</time_frame>
        <population>Women with viral load data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Arms 1 and 2: Maternal DTG+FTC/TAF and DTG+FTC/TDF</title>
            <description>Combined group of mothers randomized to receive dolutegravir DTG+FTC/TAF or DTG+FTC/TDF</description>
          </group>
          <group group_id="O2">
            <title>Arm 3: Maternal EFV/FTC/TDF</title>
            <description>Mothers randomized to receive EFV/FTC/TDF</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First HIV-1 RNA Less Than 200 Copies/mL Through Delivery</title>
          <description>Time to first viral HIV-1 RNA less than 200 copies/mL through delivery, determined using real-time results obtained from site laboratories</description>
          <population>Women with viral load data available.</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="0.09"/>
                    <measurement group_id="O2" value="6.49" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Kaplan-Meier</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Mothers With Virologic Success of HIV-1 RNA Less Than 200 Copies/mL at Delivery Based on FDA Snapshot Algorithm</title>
        <description>Percentage of mothers with virologic success of HIV-1 RNA less than 200 copies/mL at delivery based on FDA snapshot algorithm using real-time test results obtained from site laboratories</description>
        <time_frame>Delivery</time_frame>
        <population>Enrolled women</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Maternal DTG+FTC/TAF</title>
            <description>Mothers randomized to receive DTG+FTC/TAF</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Maternal DTG+FTC/TDF</title>
            <description>Mothers randomized to receive DTG+FTC/TDF</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Maternal EFV/FTC/TDF</title>
            <description>Mothers randomized to receive EFV/FTC/TDF</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Mothers With Virologic Success of HIV-1 RNA Less Than 200 Copies/mL at Delivery Based on FDA Snapshot Algorithm</title>
          <description>Percentage of mothers with virologic success of HIV-1 RNA less than 200 copies/mL at delivery based on FDA snapshot algorithm using real-time test results obtained from site laboratories</description>
          <population>Enrolled women</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9"/>
                    <measurement group_id="O2" value="92.6"/>
                    <measurement group_id="O3" value="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference between arms with null hypothesis of no difference (DTG+FTC/TAF - DTG+FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>3.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>9.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference between arms with null hypothesis of no difference (DTG+FTC/TDF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-11.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.9</ci_lower_limit>
            <ci_upper_limit>-5.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference between arms with null hypothesis of no difference (DTG+FTC/TAF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-7.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.6</ci_lower_limit>
            <ci_upper_limit>-1.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Mothers With Virologic Success of HIV-1 RNA Less Than 200 Copies/mL at 50 Weeks Postpartum Based on FDA Snapshot Algorithm</title>
        <description>Percentage of mothers with virologic success of HIV-1 RNA less than 200 copies/mL at 50 weeks postpartum based on FDA snapshot algorithm using real-time test results obtained from site laboratories</description>
        <time_frame>50 weeks postpartum</time_frame>
        <population>Enrolled women</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Maternal DTG+FTC/TAF</title>
            <description>Mothers randomized to receive DTG+FTC/TAF</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Maternal DTG+FTC/TDF</title>
            <description>Mothers randomized to receive DTG+FTC/TDF</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Maternal EFV/FTC/TDF</title>
            <description>Mothers randomized to receive EFV/FTC/TDF</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Mothers With Virologic Success of HIV-1 RNA Less Than 200 Copies/mL at 50 Weeks Postpartum Based on FDA Snapshot Algorithm</title>
          <description>Percentage of mothers with virologic success of HIV-1 RNA less than 200 copies/mL at 50 weeks postpartum based on FDA snapshot algorithm using real-time test results obtained from site laboratories</description>
          <population>Enrolled women</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.6"/>
                    <measurement group_id="O2" value="77.7"/>
                    <measurement group_id="O3" value="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference between arms with null hypothesis of no difference (DTG+FTC/TAF - DTG+FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.61</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.9</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference between arms with null hypothesis of no difference (DTG+FTC/TDF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>6.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference between arms with null hypothesis of no difference (DTG+FTC/TAF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.4</ci_lower_limit>
            <ci_upper_limit>8.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Mother-Infant Pairs With an Adverse Pregnancy Outcome</title>
        <description>Percentage of mother-infant pairs with an adverse pregnancy outcome. Adverse pregnancy outcome includes spontaneous abortion (&lt;20 weeks gestation), stillbirth (≥20 weeks gestation), preterm delivery (&lt;37 completed weeks), or small for gestational age (&lt;10th percentile per INTERGROWTH 21st Standards)</description>
        <time_frame>Delivery</time_frame>
        <population>Mother-infant pairs with pregnancy outcome evaluated on study</population>
        <group_list>
          <group group_id="O1">
            <title>Arms 1 and 2: Maternal DTG+FTC/TAF and DTG+FTC/TDF</title>
            <description>Combined group of mothers randomized to receive dolutegravir DTG+FTC/TAF or DTG+FTC/TDF</description>
          </group>
          <group group_id="O2">
            <title>Arm 3: Maternal EFV/FTC/TDF</title>
            <description>Mothers randomized to receive EFV/FTC/TDF</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Mother-Infant Pairs With an Adverse Pregnancy Outcome</title>
          <description>Percentage of mother-infant pairs with an adverse pregnancy outcome. Adverse pregnancy outcome includes spontaneous abortion (&lt;20 weeks gestation), stillbirth (≥20 weeks gestation), preterm delivery (&lt;37 completed weeks), or small for gestational age (&lt;10th percentile per INTERGROWTH 21st Standards)</description>
          <population>Mother-infant pairs with pregnancy outcome evaluated on study</population>
          <units>percentage of mother-infant pairs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4"/>
                    <measurement group_id="O2" value="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between groups (DTG groups - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>4.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>11.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Probability of Women Experiencing Grade 3 or Higher Adverse Event</title>
        <description>The Kaplan-Meier estimate of the cumulative probability of women experiencing grade 3 or higher adverse events, including events resulting in death due to any cause.&#xD;
Time to first maternal grade 3 or higher adverse event was defined as the first grade 3 or higher adverse event that occurred after randomization and before 74 weeks of follow-up. The timeframe of 74 weeks was determined by adding up 56 weeks of postpartum follow-up to the mean duration of antepartum follow-up, which was 18 weeks.</description>
        <time_frame>From randomization up to 74 weeks</time_frame>
        <population>Enrolled women.</population>
        <group_list>
          <group group_id="O1">
            <title>Arms 1 and 2: Maternal DTG+FTC/TAF and DTG+FTC/TDF</title>
            <description>Combined group of mothers randomized to receive dolutegravir DTG+FTC/TAF or DTG+FTC/TDF</description>
          </group>
          <group group_id="O2">
            <title>Arm 3: Maternal EFV/FTC/TDF</title>
            <description>Mothers randomized to receive EFV/FTC/TDF</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Probability of Women Experiencing Grade 3 or Higher Adverse Event</title>
          <description>The Kaplan-Meier estimate of the cumulative probability of women experiencing grade 3 or higher adverse events, including events resulting in death due to any cause.&#xD;
Time to first maternal grade 3 or higher adverse event was defined as the first grade 3 or higher adverse event that occurred after randomization and before 74 weeks of follow-up. The timeframe of 74 weeks was determined by adding up 56 weeks of postpartum follow-up to the mean duration of antepartum follow-up, which was 18 weeks.</description>
          <population>Enrolled women.</population>
          <units>Cumulative probability per 100 persons</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                    <measurement group_id="O2" value="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The Kaplan-Meier method was used to estimate survival probabilities. Comparisons of survival probabilities was based on a Z-test using Greenwoods estimate of the standard error. The null hypothesis was no difference between arms, with estimate of risk difference combined DTG arms-EFV/FTC/TDF.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>Z-test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.6</ci_lower_limit>
            <ci_upper_limit>7.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Probability of Infants Experiencing Grade 3 or Higher Adverse Event</title>
        <description>The Kaplan-Meier estimate of the cumulative probability of infants experiencing grade 3 or higher adverse events, including events resulting in death due to any cause.</description>
        <time_frame>Birth through Week 50 postpartum</time_frame>
        <population>Live born infants</population>
        <group_list>
          <group group_id="O1">
            <title>Arms 1 and 2 Infants</title>
            <description>Combined group of infants born to women who were randomized to receive DTG+FTC/TAF or DTG+FTC/TDF during pregnancy and postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm 3 Infants</title>
            <description>Infants born to women who were randomized to receive EFV/FTC/TDF during pregnancy and postpartum</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Probability of Infants Experiencing Grade 3 or Higher Adverse Event</title>
          <description>The Kaplan-Meier estimate of the cumulative probability of infants experiencing grade 3 or higher adverse events, including events resulting in death due to any cause.</description>
          <population>Live born infants</population>
          <units>Cumulative probability per 100 persons</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8"/>
                    <measurement group_id="O2" value="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The Kaplan-Meier method was used to estimate survival probabilities. Comparisons of survival probabilities was based on a Z-test using Greenwoods estimate of the standard error. The null hypothesis was no difference between arms, with estimated difference of combined DTG arms - EFV/FTC/TDF.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Z-test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.8</ci_lower_limit>
            <ci_upper_limit>12.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Mother-infant Pairs With an Adverse Pregnancy Outcome or Major Congenital Anomaly</title>
        <description>Percentage of mother-infant pairs with an adverse pregnancy outcome or major congenital anomaly. Adverse pregnancy outcomes include spontaneous abortions (&lt;20 weeks gestation), stillbirths (≥20 weeks gestation), preterm deliveries (&lt;37 weeks gestation), and infants small for gestational age (&lt;10th percentile per INTERGROWTH 21st Standards). Major congenital anomaly was defined consistent with the definition of malformation provided by Holmes and Westgate (i.e., a structural abnormality with surgical, medical, or cosmetic importance) and evaluated by an internal study team blinded to treatment arm.</description>
        <time_frame>Delivery through 50 weeks postpartum</time_frame>
        <population>Mother-infant pairs with pregnancy outcome evaluated on study.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Maternal DTG+FTC/TAF</title>
            <description>Mothers randomized to receive DTG+FTC/TAF</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Maternal DTG+FTC/TDF</title>
            <description>Mothers randomized to receive DTG+FTC/TDF</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Maternal EFV/FTC/TDF</title>
            <description>Mothers randomized to receive EFV/FTC/TDF</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Mother-infant Pairs With an Adverse Pregnancy Outcome or Major Congenital Anomaly</title>
          <description>Percentage of mother-infant pairs with an adverse pregnancy outcome or major congenital anomaly. Adverse pregnancy outcomes include spontaneous abortions (&lt;20 weeks gestation), stillbirths (≥20 weeks gestation), preterm deliveries (&lt;37 weeks gestation), and infants small for gestational age (&lt;10th percentile per INTERGROWTH 21st Standards). Major congenital anomaly was defined consistent with the definition of malformation provided by Holmes and Westgate (i.e., a structural abnormality with surgical, medical, or cosmetic importance) and evaluated by an internal study team blinded to treatment arm.</description>
          <population>Mother-infant pairs with pregnancy outcome evaluated on study.</population>
          <units>percentage of mother-infant pairs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="213"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1"/>
                    <measurement group_id="O2" value="32.9"/>
                    <measurement group_id="O3" value="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between groups (DTG+FTC/TAF - DTG+FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.043</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-8.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.3</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between groups (DTG+FTC/TDF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.3</ci_lower_limit>
            <ci_upper_limit>8.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between groups (DTG+FTC/TAF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-9.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.6</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Mother-infant Pairs in the Classified Ranked Composite Safety Outcome</title>
        <description>Infant and pregnancy outcomes were classified on a scale of 1 to 10, with mother-infant pairs categorized by the worst outcome they experienced (worst category being 1 and best being 10): 1) Infant death; 2) Spontaneous abortion (&lt;20 weeks gestation) or stillbirth (≥20 weeks gestation); 3) Infant HIV infection; 4) Extremely and very early preterm (&lt;32 completed weeks); 5) Major congenital anomaly; 6) Preterm delivery (&lt;37 completed weeks); 7) Small for gestational age (&lt;10th percentile); 8) Infant hospitalization; 9) Infant grade 3 or 4 adverse event; 10) None of the above. If a mother-infant pair experienced more than one safety outcome, only the worst was reported.</description>
        <time_frame>Birth through 50 weeks postpartum</time_frame>
        <population>Mother-infant pairs with pregnancy outcome evaluated on study.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Maternal DTG+FTC/TAF</title>
            <description>Mothers randomized to receive DTG+FTC/TAF</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Maternal DTG+FTC/TDF</title>
            <description>Mothers randomized to receive DTG+FTC/TDF</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Maternal EFV/FTC/TDF</title>
            <description>Mothers randomized to receive EFV/FTC/TDF</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Mother-infant Pairs in the Classified Ranked Composite Safety Outcome</title>
          <description>Infant and pregnancy outcomes were classified on a scale of 1 to 10, with mother-infant pairs categorized by the worst outcome they experienced (worst category being 1 and best being 10): 1) Infant death; 2) Spontaneous abortion (&lt;20 weeks gestation) or stillbirth (≥20 weeks gestation); 3) Infant HIV infection; 4) Extremely and very early preterm (&lt;32 completed weeks); 5) Major congenital anomaly; 6) Preterm delivery (&lt;37 completed weeks); 7) Small for gestational age (&lt;10th percentile); 8) Infant hospitalization; 9) Infant grade 3 or 4 adverse event; 10) None of the above. If a mother-infant pair experienced more than one safety outcome, only the worst was reported.</description>
          <population>Mother-infant pairs with pregnancy outcome evaluated on study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="213"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Infant Death</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Spontaneous abortion or stillbirth</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>HIV-1 Infection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extremely and Very Preterm Delivery</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Major Congenital Anomaly</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Preterm Delivery</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Small for Gestational Age</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Infant Hospitalization</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Infant Grade 3 or 4 Adverse Event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of odds ratio equal to 1, with odds of experiencing a worse outcome equal between groups (DTG+FTC/TAF - DTG+FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.095</p_value>
            <method>Regression, Ordinal</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of odds ratio equal to 1, with odds of experiencing a worse outcome equal between groups (DTG+FTC/TDF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>Regression, Ordinal</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of odds ratio equal to 1, with odds of experiencing a worse outcome equal between groups (DTG+FTC/TAF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Regression, Ordinal</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Probability of Infant HIV-infection</title>
        <description>The Kaplan-Meier estimate of the cumulative probability of infants acquiring HIV-1 infection from birth through 50 weeks after birth based on nucleic acid test results.</description>
        <time_frame>Birth through 50 weeks after birth</time_frame>
        <population>Live born infants</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 Infants</title>
            <description>Infants born to women who were randomized to receive DTG+FTC/TAF during pregnancy and postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 Infants</title>
            <description>Infants born to women who were randomized to receive DTG+FTC/TDF during pregnancy and postpartum</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 Infants</title>
            <description>Infants born to women who were randomized to receive EFV/FTC/TDF during pregnancy and postpartum</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Probability of Infant HIV-infection</title>
          <description>The Kaplan-Meier estimate of the cumulative probability of infants acquiring HIV-1 infection from birth through 50 weeks after birth based on nucleic acid test results.</description>
          <population>Live born infants</population>
          <units>Cumulative probability per 100 persons</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98"/>
                    <measurement group_id="O2" value="0.50"/>
                    <measurement group_id="O3" value="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The Kaplan-Meier method was used to estimate survival probabilities. Survival probabilities were compared based on a Z-test using Greenwoods estimate of the standard error. The null hypothesis was no difference between arms (DTG+FTC/TAF - DTG+FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Z-test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The Kaplan-Meier method was used to estimate survival probabilities. Survival probabilities were compared based on a Z-test using Greenwoods estimate of the standard error. The null hypothesis was no difference between arms (DTG+FTC/TDF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.47</p_value>
            <method>Z-test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The Kaplan-Meier method was used to estimate survival probabilities. Survival probabilities were compared based on a Z-test using Greenwoods estimate of the standard error. The null hypothesis was no difference between arms (DTG+FTC/TAF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>Z-test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Probability of Infant Deaths</title>
        <description>The Kaplan-Meier estimate of the cumulative probability of infant deaths from birth through 50 weeks after birth.</description>
        <time_frame>Birth through 50 weeks after birth</time_frame>
        <population>Live born infants</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 Infants</title>
            <description>Infants born to women who were randomized to receive DTG+FTC/TAF during pregnancy and postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 Infants</title>
            <description>Infants born to women who were randomized to receive DTG+FTC/TDF during pregnancy and postpartum</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 Infants</title>
            <description>Infants born to women who were randomized to receive EFV/FTC/TDF during pregnancy and postpartum</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Probability of Infant Deaths</title>
          <description>The Kaplan-Meier estimate of the cumulative probability of infant deaths from birth through 50 weeks after birth.</description>
          <population>Live born infants</population>
          <units>Cumulative probability per 100 persons</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The Kaplan-Meier method was used to estimate survival probabilities. Comparisons of survival probabilities was based on a Z-test using Greenwoods estimate of the standard error. The null hypothesis was no difference between arms, with estimated difference of DTG+FTC/TAF - DTG+FTC/TDF.</non_inferiority_desc>
            <p_value>0.20</p_value>
            <method>Z-test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The Kaplan-Meier method was used to estimate survival probabilities. Comparisons of survival probabilities was based on a Z-test using Greenwoods estimate of the standard error. The null hypothesis was no difference between arms, with estimate of risk difference DTG+FTC/TDF-EFV/FTC/TDF.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Z-test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.9</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The Kaplan-Meier method was used to estimate survival probabilities. Comparisons of survival probabilities was based on a Z-test using Greenwoods estimate of the standard error. The null hypothesis was no difference between arms, with estimate of risk difference DTG+FTC/TAF-EFV/FTC/TDF.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Z-test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-5.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.7</ci_lower_limit>
            <ci_upper_limit>-2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Change in Creatinine Clearance</title>
        <description>Maternal change in creatinine clearance per week based on generalized estimating equations</description>
        <time_frame>Baseline to 50 weeks postpartum</time_frame>
        <population>Women with creatinine clearance data.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Maternal DTG+FTC/TAF</title>
            <description>Mothers randomized to receive DTG+FTC/TAF</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Maternal DTG+FTC/TDF</title>
            <description>Mothers randomized to receive DTG+FTC/TDF</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Maternal EFV/FTC/TDF</title>
            <description>Mothers randomized to receive EFV/FTC/TDF</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Change in Creatinine Clearance</title>
          <description>Maternal change in creatinine clearance per week based on generalized estimating equations</description>
          <population>Women with creatinine clearance data.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="214"/>
                <count group_id="O3" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.980" lower_limit="-1.066" upper_limit="-0.894"/>
                    <measurement group_id="O2" value="-0.887" lower_limit="-0.964" upper_limit="-0.810"/>
                    <measurement group_id="O3" value="-0.935" lower_limit="-1.013" upper_limit="-0.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference in weekly change in creatinine clearance from baseline (DTG+FTC/TAF - DTG+FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Generalized Estimating Equation</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.093</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.208</ci_lower_limit>
            <ci_upper_limit>0.023</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference in weekly change in creatinine clearance from baseline (DTG+FTC/TDF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.39</p_value>
            <method>Generalized Estimating Equation</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.048</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.061</ci_lower_limit>
            <ci_upper_limit>0.158</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference in weekly change in creatinine clearance from baseline (DTG+FTC/TAF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>Generalized Estimating Equation</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.045</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.161</ci_lower_limit>
            <ci_upper_limit>0.072</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infant Creatinine Clearance</title>
        <description>Infant creatinine clearance based on Schwartz formula</description>
        <time_frame>Delivery and 26 weeks postpartum</time_frame>
        <population>Live born infants with creatinine clearance data</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 Infants</title>
            <description>Infants born to women who were randomized to receive DTG+FTC/TAF during pregnancy and postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 Infants</title>
            <description>Infants born to women who were randomized to receive DTG+FTC/TDF during pregnancy and postpartum</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 Infants</title>
            <description>Infants born to women who were randomized to receive EFV/FTC/TDF during pregnancy and postpartum</description>
          </group>
        </group_list>
        <measure>
          <title>Infant Creatinine Clearance</title>
          <description>Infant creatinine clearance based on Schwartz formula</description>
          <population>Live born infants with creatinine clearance data</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Delivery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.7" spread="29.6"/>
                    <measurement group_id="O2" value="53.1" spread="69.7"/>
                    <measurement group_id="O3" value="49.0" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>26 Weeks Postpartum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.8" spread="109.6"/>
                    <measurement group_id="O2" value="123.6" spread="40.3"/>
                    <measurement group_id="O3" value="135.0" spread="51.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between arms at delivery (DTG+FTC/TAF - DTG+FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.94</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.3</ci_lower_limit>
            <ci_upper_limit>10.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between arms at delivery (DTG+FTC/TDF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.5</ci_lower_limit>
            <ci_upper_limit>14.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between arms at delivery (DTG+FTC/TAF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>9.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between arms at week 26 (DTG+FTC/TAF - DTG+FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.9</ci_lower_limit>
            <ci_upper_limit>31.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between arms at week 26 (DTG+FTC/TDF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.6</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between arms at week 26 (DTG+FTC/TAF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.0</ci_lower_limit>
            <ci_upper_limit>20.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Mothers With HIV-1 ARV Drug Resistance Mutations at the Time of Maternal Virologic Failure</title>
        <description>Percentage of mothers with HIV-1 antiretroviral (ARV) drug resistance mutations at the time of maternal virologic failure. Virologic failure was defined as two consecutive plasma HIV-1 RNA viral loads &lt;200 copies/mL on or after 24 weeks on study. Drug resistance mutations were assessed using the Stanford algorithm, and all ARV regimens were assessed for mutations.</description>
        <time_frame>From 24 weeks after randomization through Week 50 postpartum</time_frame>
        <population>All enrolled women</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Maternal DTG+FTC/TAF</title>
            <description>Mothers randomized to receive DTG+FTC/TAF</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Maternal DTG+FTC/TDF</title>
            <description>Mothers randomized to receive DTG+FTC/TDF</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Maternal EFV/FTC/TDF</title>
            <description>Mothers randomized to receive EFV/FTC/TDF</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Mothers With HIV-1 ARV Drug Resistance Mutations at the Time of Maternal Virologic Failure</title>
          <description>Percentage of mothers with HIV-1 antiretroviral (ARV) drug resistance mutations at the time of maternal virologic failure. Virologic failure was defined as two consecutive plasma HIV-1 RNA viral loads &lt;200 copies/mL on or after 24 weeks on study. Drug resistance mutations were assessed using the Stanford algorithm, and all ARV regimens were assessed for mutations.</description>
          <population>All enrolled women</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92"/>
                    <measurement group_id="O2" value="1.86"/>
                    <measurement group_id="O3" value="6.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between groups (DTG+FTC/TAF - DTG+FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between groups (DTG+FTC/TDF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.0</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between groups (DTG+FTC/TAF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.7</ci_lower_limit>
            <ci_upper_limit>-1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Infants With HIV-1 Antiretroviral Drug Resistance Mutations at the Time of Infant HIV Diagnosis</title>
        <description>Percentage of infants with HIV-1 antiretroviral drug resistance mutations at the time of infant HIV diagnosis, based on laboratory blood test results.&#xD;
Data for this outcome are not yet available because shipping delays due to COVID-19.</description>
        <time_frame>From birth through 50 weeks postpartum</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Preterm Deliveries</title>
        <description>Percentage of preterm deliveries (&lt;37 weeks gestation)</description>
        <time_frame>Delivery</time_frame>
        <population>Women with pregnancies resulting in a live born infant</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Maternal DTG+FTC/TAF</title>
            <description>Mothers randomized to receive DTG+FTC/TAF</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Maternal DTG+FTC/TDF</title>
            <description>Mothers randomized to receive DTG+FTC/TDF</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Maternal EFV/FTC/TDF</title>
            <description>Mothers randomized to receive EFV/FTC/TDF</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Preterm Deliveries</title>
          <description>Percentage of preterm deliveries (&lt;37 weeks gestation)</description>
          <population>Women with pregnancies resulting in a live born infant</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="9.4"/>
                    <measurement group_id="O3" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin was a 10% difference between groups.</non_inferiority_desc>
            <p_value>0.16</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-3.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.8</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin was a 10% difference between groups.</non_inferiority_desc>
            <p_value>0.38</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.7</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin was a 10% difference between groups.</non_inferiority_desc>
            <p_value>0.023</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-6.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.8</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Infants Born Small for Gestational Age</title>
        <description>Percentage of infants born small for gestational age (&lt;10th percentile adjusted for sex assigned at birth) based on Intergrowth 21st Standards</description>
        <time_frame>Birth</time_frame>
        <population>Live born infants with weight and sex data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 Infants</title>
            <description>Infants born to women who were randomized to receive DTG+FTC/TAF during pregnancy and postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 Infants</title>
            <description>Infants born to women who were randomized to receive DTG+FTC/TDF during pregnancy and postpartum</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 Infants</title>
            <description>Infants born to women who were randomized to receive EFV/FTC/TDF during pregnancy and postpartum</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Infants Born Small for Gestational Age</title>
          <description>Percentage of infants born small for gestational age (&lt;10th percentile adjusted for sex assigned at birth) based on Intergrowth 21st Standards</description>
          <population>Live born infants with weight and sex data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="22.5"/>
                    <measurement group_id="O3" value="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin was a 10% difference between groups.</non_inferiority_desc>
            <p_value>0.12</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-6.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.9</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin was a 10% difference between groups.</non_inferiority_desc>
            <p_value>0.63</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.0</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin was a 10% difference between groups.</non_inferiority_desc>
            <p_value>0.28</p_value>
            <method>Wald test of two proportions</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.7</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Maternal Weight Antepartum</title>
        <description>Change in maternal antepartum weight per week based on generalized estimating equations</description>
        <time_frame>Baseline through before delivery (up to one day prior)</time_frame>
        <population>Women with weight data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Maternal DTG+FTC/TAF</title>
            <description>Mothers randomized to receive DTG+FTC/TAF</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Maternal DTG+FTC/TDF</title>
            <description>Mothers randomized to receive DTG+FTC/TDF</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Maternal EFV/FTC/TDF</title>
            <description>Mothers randomized to receive EFV/FTC/TDF</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Maternal Weight Antepartum</title>
          <description>Change in maternal antepartum weight per week based on generalized estimating equations</description>
          <population>Women with weight data available.</population>
          <units>kg/week</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.378" lower_limit="0.343" upper_limit="0.412"/>
                    <measurement group_id="O2" value="0.319" lower_limit="0.291" upper_limit="0.348"/>
                    <measurement group_id="O3" value="0.291" lower_limit="0.260" upper_limit="0.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between arms (DTG+FTC/TAF - DTG+FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Generalized Estimating Equation</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.058</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.013</ci_lower_limit>
            <ci_upper_limit>0.103</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between arms (DTG+FTC/TDF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Generalized Estimating Equation</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.028</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.014</ci_lower_limit>
            <ci_upper_limit>0.070</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between arms (DTG+FTC/TAF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Generalized Estimating Equation</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.086</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.040</ci_lower_limit>
            <ci_upper_limit>0.133</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Maternal Weight Postpartum</title>
        <description>Change in maternal postpartum weight per week based on generalized estimating equations</description>
        <time_frame>Delivery to 50 weeks postpartum</time_frame>
        <population>Women with weight data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Maternal DTG+FTC/TAF</title>
            <description>Mothers randomized to receive DTG+FTC/TAF</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Maternal DTG+FTC/TDF</title>
            <description>Mothers randomized to receive DTG+FTC/TDF</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Maternal EFV/FTC/TDF</title>
            <description>Mothers randomized to receive EFV/FTC/TDF</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Maternal Weight Postpartum</title>
          <description>Change in maternal postpartum weight per week based on generalized estimating equations</description>
          <population>Women with weight data available.</population>
          <units>kg/week</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.014" lower_limit="-0.004" upper_limit="0.032"/>
                    <measurement group_id="O2" value="-0.008" lower_limit="-0.027" upper_limit="0.012"/>
                    <measurement group_id="O3" value="-0.032" lower_limit="-0.048" upper_limit="-0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between arms (DTG+FTC/TAF - DTG+FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Generalized Estimating Equation</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.022</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.005</ci_lower_limit>
            <ci_upper_limit>0.048</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between arms (DTG+FTC/TDF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.055</p_value>
            <method>Generalized Estimating Equation</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.024</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.000</ci_lower_limit>
            <ci_upper_limit>0.049</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between arms (DTG+FTC/TAF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Generalized Estimating Equation</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.046</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.022</ci_lower_limit>
            <ci_upper_limit>0.070</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Maternal Weight Overall</title>
        <description>Change in maternal weight per week based on generalized estimating equations</description>
        <time_frame>Baseline to 50 weeks postpartum</time_frame>
        <population>Women with weight data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Maternal DTG+FTC/TAF</title>
            <description>Mothers randomized to receive DTG+FTC/TAF</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Maternal DTG+FTC/TDF</title>
            <description>Mothers randomized to receive DTG+FTC/TDF</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Maternal EFV/FTC/TDF</title>
            <description>Mothers randomized to receive EFV/FTC/TDF</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Maternal Weight Overall</title>
          <description>Change in maternal weight per week based on generalized estimating equations</description>
          <population>Women with weight data available.</population>
          <units>kg/week</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.027" lower_limit="-0.042" upper_limit="-0.012"/>
                    <measurement group_id="O2" value="-0.050" lower_limit="-0.066" upper_limit="-0.034"/>
                    <measurement group_id="O3" value="-0.084" lower_limit="-0.098" upper_limit="-0.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between arms (DTG+FTC/TAF - DTG+FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>Generalized Estimating Equation</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.023</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.001</ci_lower_limit>
            <ci_upper_limit>0.045</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between arms (DTG+FTC/TDF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Generalized Estimating Equation</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.034</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.013</ci_lower_limit>
            <ci_upper_limit>0.055</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between arms (DTG+FTC/TAF - EFV/FTC/TDF).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Generalized Estimating Equation</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.057</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.036</ci_lower_limit>
            <ci_upper_limit>0.078</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For women, adverse events were reported from randomization through study visit occurring at 50 weeks postpartum. For infants, adverse events were reported from birth through the study visit occurring at 50 weeks post birth.</time_frame>
      <desc>All grade 3 or higher and serious adverse events were reported. Other targeted lower grade adverse events. All randomized women and live born infants were summarized. The DAIDS AE Grading Table, Corrected Version 2.1, dated July 2017, was used in this study. A full description of adverse event data collection is provided in protocol Section 7.2.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: Maternal DTG+FTC/TAF</title>
          <description>Mothers randomized to receive DTG+FTC/TAF</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: Maternal DTG+FTC/TDF</title>
          <description>Mothers randomized to receive DTG+FTC/TDF</description>
        </group>
        <group group_id="E3">
          <title>Arm 3: Maternal EFV/FTC/TDF</title>
          <description>Mothers randomized to receive EFV/FTC/TDF</description>
        </group>
        <group group_id="E4">
          <title>Arm 1 Infants</title>
          <description>Infants born to women who were randomized to receive DTG+FTC/TAF during pregnancy and postpartum</description>
        </group>
        <group group_id="E5">
          <title>Arm 2 Infants</title>
          <description>Infants born to women who were randomized to receive DTG+FTC/TDF during pregnancy and postpartum</description>
        </group>
        <group group_id="E6">
          <title>Arm 3 Infants</title>
          <description>Infants born to women who were randomized to receive EFV/FTC/TDF during pregnancy and postpartum</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="44" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Anaemia neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Anaemia of pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Neutropenia neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Accessory auricle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Ankyloglossia congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Anomalous pulmonary venous connection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Arachnodactyly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Congenital foot malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Congenital inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Congenital joint malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Congenital mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Congenital skin dimples</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Congenital syphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Congenital tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Congenital ureteric anomaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Duodenal atresia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Haemangioma congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Macrocephaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Multiple congenital abnormalities</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Naevus flammeus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Patent ductus arteriosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Sickle cell anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Sickle cell disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Talipes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Ileal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Infantile vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Fever neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Amniotic cavity infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Meningitis pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Neonatal pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Postpartum sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pyometra</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Staphylococcal scalded skin syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Urinary tract infection neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Uterine rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Burkitt's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Fontanelle bulging</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Infant irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Muscle contractions involuntary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Neonatal seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Birth trauma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Cervix dystocia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Failed induction of labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Failed trial of labour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>False labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Foetal death</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Foetal distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Foetal growth restriction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Foetal hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Gestational diabetes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Gestational hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Haemorrhage in pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hydrops foetalis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hypothermia neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Imminent abortion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Jaundice neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Large for dates baby</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Low birth weight baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Meconium in amniotic fluid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Neonatal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Oligohydramnios</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Placenta praevia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Premature delivery</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Premature separation of placenta</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Preterm premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Prolonged labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Prolonged pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Prolonged rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Threatened labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Umbilical cord around neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Umbilical cord cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Umbilical cord prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Uterine atony</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pyelocaliectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grunting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Meconium aspiration syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Neonatal asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Neonatal tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Transient tachypnoea of the newborn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Use of accessory respiratory muscles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pyoderma gangrenosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Rash neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Physical assault</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="189" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="198" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="143" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Anaemia of chronic disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Anaemia of pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital joint malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Congenital toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Congenital umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Polydactyly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Trisomy 21</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Developmental delay</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Macrosomia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Immune reconstitution inflammatory syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Amniotic cavity infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Genital herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Perihepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Postpartum sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Tuberculous pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis trichomonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="179" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" subjects_affected="182" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="193" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="132" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Head lag</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Poor feeding infant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Underweight</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acrochordon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Poor sucking reflex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Foetal distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Gestational diabetes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Gestational hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Jaundice neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Low birth weight baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Meconium in amniotic fluid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Morning sickness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Oligohydramnios</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Premature delivery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Preterm premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Prolonged pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Small for dates baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Perinatal depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Neonatal asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Neonatal tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Transient tachypnoea of the newborn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Urticaria papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Caesarean section</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>IMPAACT Clinicaltrials.gov Coordinator</name_or_title>
      <organization>Family Health International (FHI 360)</organization>
      <phone>(919) 405-1429</phone>
      <email>IMPAACT.ctgov@fstrf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

